<DOC>
	<DOC>NCT02834390</DOC>
	<brief_summary>This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of the combination of quizartinib and induction and consolidation chemotherapy.</brief_summary>
	<brief_title>Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>No prior treatment for AML (including quizartinib) ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 to 2 Diagnosis of acute promyelocytic leukemia Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>phase 1</keyword>
	<keyword>hematology</keyword>
	<keyword>malignancy</keyword>
	<keyword>newly diagnosed</keyword>
</DOC>